Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863) (en)
|
http://linked.open...y/drugbank/dosage
| |
http://linked.open...gy/drugbank/group
| |
http://linked.open...drugbank/halfLife
| - In patients with normal renal function, 3 to 4 hours. In patients with impaired renal function, up to 8 hours. (en)
|
http://linked.open...ugbank/indication
| - For use, as an adjunct, in the treatment of pulmonary tuberculosis. (en)
|
http://linked.open...bank/manufacturer
| |
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - Ethambutol inhibits arabinosyl transferases which is involved in cell wall biosynthesis. By inhibiting this enzyme, the bacterial cell wall complex production is inhibited. This leads to an increase in cell wall permeability. (en)
|
http://linked.open...drugbank/packager
| |
http://linked.open...outeOfElimination
| - During the 24-hour period following oral administration of ethambutol hydrochloride approximately 50 percent of the initial dose is excreted unchanged in the urine, while an additional 8 to 15 percent appears in the form of metabolites. From 20 to 22 percent of the initial dose is excreted in the feces as unchanged drug. (en)
|
http://linked.open.../drugbank/synonym
| - Ethambutol (en)
- EMB (en)
- (+)-2,2'-(ethylenediimino)di-1-butanol (en)
- (+)-S,S-ethambutol (en)
- (+)-ethambutol (en)
- (2S,7S)-2,7-Diethyl-3,6-diazaoctane-1,8-diol (en)
- (S,S)-Ethambutol (en)
- Etambutol (en)
- Etambutolo (en)
- Ethambutolum (en)
- S,S-Ethambutol (en)
- (+)-N,N'-bis(1-(hydroxymethyl)propyl)ethylenediamine (en)
|
http://linked.open...drugbank/toxicity
| - The most commonly recognized toxic effect of ethambutol is optic neuropathy, which generally is considered uncommon and reversible in medical literature. Other side effects that have been observed are pruritus, joint pain, gastrointestinal upset, abdominal pain, malaise, headache, dizziness, mental confusion, disorientation, and possible hallucinations. (en)
|
http://linked.open.../drug/hasAHFSCode
| |
http://linked.open...k/foodInteraction
| - Take with food to reduce irritation. (en)
|
http://linked.open...nk/proteinBinding
| |
http://linked.open...ogy/drugbank/salt
| |
http://linked.open...ynthesisReference
| - Sang-Woo Park, "Preparation of ethambutol-diisoniazide methane sulfonic acid salt." U.S. Patent US4450274, issued February, 1973. (en)
|
foaf:page
| |
http://linked.open...ugbank/IUPAC-Name
| |
http://linked.open...gy/drugbank/InChI
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open...noisotopic-Weight
| |
http://linked.open...y/drugbank/SMILES
| |
http://linked.open.../Water-Solubility
| |
http://linked.open...ogy/drugbank/logP
| |
http://linked.open...ogy/drugbank/logS
| |
http://linked.open...l/drug/hasATCCode
| |
http://linked.open...nd-Acceptor-Count
| |
http://linked.open...-Bond-Donor-Count
| |
http://linked.open...drugbank/InChIKey
| |
http://linked.open...urface-Area--PSA-
| |
http://linked.open...nk/Polarizability
| |
http://linked.open...bank/Refractivity
| |
http://linked.open...atable-Bond-Count
| |
http://linked.open...ugbank/absorption
| - About 75% to 80% of an orally administered dose of ethambutol is absorbed from the gastrointestinal tract. (en)
|
http://linked.open.../affectedOrganism
| - Humans and other mammals (en)
- Mycobacterium tuberculosis (en)
|
http://linked.open...casRegistryNumber
| |
http://linked.open...drugbank/category
| |
http://linked.open...gbank/containedIn
| |
http://linked.open...k/Bioavailability
| |
http://linked.open...bank/Ghose-Filter
| |
http://linked.open...nk/MDDR-Like-Rule
| |